Get the Stockscreener App
2.36
7.27%
0.16
After Hours:
2.35
-0.010
-0.42%
Grace Therapeutics Inc stock is traded at $2.36, with a volume of 525.71K.
It is up +7.27% in the last 24 hours and up +2.61% over the past month.
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.
See More
Previous Close:
$2.20
Open:
$2.21
24h Volume:
525.71K
Relative Volume:
0.70
Market Cap:
$36.52M
Revenue:
-
Net Income/Loss:
$-5.98M
P/E Ratio:
-6.5501
EPS:
-0.3603
Net Cash Flow:
$-9.83M
1W Performance:
+9.77%
1M Performance:
+2.61%
6M Performance:
-26.48%
1Y Performance:
-20.54%
1-Day Range:
$2.21
$2.39
1-Week Range:
$2.11
$2.39
52-Week Range:
$1.79
$5.18
Grace Therapeutics Inc Stock (GRCE) Company Profile
Name
Grace Therapeutics Inc
Sector
Industry
Phone
609-322-1602
Address
103 CARNEGIE CENTER, PRINCETON
Compare GRCE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRCE
Grace Therapeutics Inc
|
2.36 | 34.04M | 0 | -5.98M | -9.83M | -0.3603 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Grace Therapeutics Inc Stock (GRCE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-02-25 | Initiated | TD Cowen | Buy |
| Sep-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-20 | Upgrade | B. Riley FBR | Neutral → Buy |
| Jan-13-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-29-19 | Initiated | B. Riley FBR | Buy |
| Jul-18-19 | Initiated | Oppenheimer | Outperform |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
View All
Grace Therapeutics Inc Stock (GRCE) Latest News
GRCE Q1 2026 Earnings: EPS Surprises to the Upside Despite No RevenueAnalyst Consensus Shift - Newser
GRCE Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineGuidance Accuracy Score - Newser
Grace Therapeutics Inc. (GRCE) Q1 2026 Earnings: Narrowed Loss Beats Expectations Despite Stock DipShared Momentum Picks - Newser
GRCE Stock Chart | GRACE THERAPEUTICS INC (NASDAQ:GRCE) - ChartMill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc.GRCE - PR Newswire
GRCE Technical Analysis | Trend, Signals & Chart Patterns | GRACE THERAPEUTICS INC (NASDAQ:GRCE) - ChartMill
Pomerantz LLP Investigates Claims for Grace Therapeutics Investors - Intellectia AI
Grace Therapeutics (GRCE) Gains +1.40% — Support Holds at $2.07 2026-05-20Intraday Profile - Newser
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc.GRCE - FinancialContent
Why Is Grace Therapeutics, Inc. (GRCE) Stock Down Today? - Meyka
Grace Therapeutics (GRCE) Q1 2026 Earnings Beat: Revenue $N/A, EPS $-0.14Mature Phase - Newser
Grace Therapeutics (GRCE) price target decreased by 47.83% to 6.12 - MSN
Grace Therapeutics (GRCE) Q1 2026 Earnings: $-0.14 EPS Surges Past $-0.29 EstimatesSocial Trade Signals - newser.com
ADAR1 reports 1.72M shares in Grace Therapeutics (GRCE) - Stock Titan
Grace Therapeutics faces investigation after FDA rejects drug application, stock drops 45%. - Pluang
GRCE Stock Plunges 45% After FDA Rejects Brain Injury Drug — Company Says Concerns Are Fixable - MSN
Grace Therapeutics (GRCE) Down -1.78% — How Low Could It Go? 2026-05-14Hedge Fund Inspired Picks - Newser
Number of shareholders of Grace Therapeutics, Inc. – NASDAQ:GRCE - TradingView
Number of shareholders of Grace Therapeutics, Inc. – FWB:L8S - TradingView
Largest borrow rate increases among liquid names - TipRanks
Grace Therapeutics, Inc. (GRCE) Eps Diluted (TTM) - Zacks Investment Research
Grace Therapeutics stock falls as FDA declines to approve brain hemorrhage drug - MSN
The organic vs inorganic growth story at Grace Therapeutics (GRCE) | Grace Therapeutics 51% EPS beat tops loss viewsDebt Refinancing - newser.com
Why Grace Therapeutics (GRCE) ability to innovate sets it apart (-1.27%) 2026-05-05Price Momentum - newser.com
GRCE stock on track for worst week in 5.5 years — what’s driving the selloff? - MSN
GRCE (Grace Therapeutics) EV-to-OCF : -0.99 (As of Apr. 30, 2026) - GuruFocus
Grace Therapeutics’ GTx-104: Novel IV Nimodipine Shows Superior Efficacy and Safety for aSAH vs. Oral Standard of Care 245 - Minichart
814,000-share position reported by AIGH, Orin Hirschman in Grace Therapeutics (GRCE) - Stock Titan
Grace Therapeutics Updates GTx-104 Regulatory and Trial Progress - TipRanks
Grace Therapeutics (GRCE) outlines GTx-104 CRL, Phase 3 data and cash - Stock Titan
GRCE Options Volatility — NASDAQ:GRCE - TradingView
Grace Therapeutics Stock Falls As FDA Declines To Approve Brain Hemorrhage Drug - Sahm
Craig-Hallum Maintains Grace Therapeutics(GRCE.US) With Buy Rating, Announces Target Price $4 - Moomoo
GRCE Stock On Track For Worst Week In 5.5 Years — What’s Driving The Selloff? - Stocktwits
GRCE Maintained by TD Cowen -- Price Target Lowered to $8.00 - GuruFocus
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial - BioWorld News
Grace Therapeutics price target lowered to $8 from $12 at TD Cowen - TipRanks
Grace hit by CRL for GTx-104, shares plunge 45% - The Pharma Letter
Grace Therapeutics price target lowered to $4 from $11 at Craig-Hallum - TipRanks
Grace Therapeutics, IncFDA Does Not Reques - Moomoo
Grace Therapeutics Inc Stock (GRCE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):